E-Mail
In Alzheimer s disease, neurons in the brain die. Largely responsible for the death of neurons are certain protein deposits in the brains of affected individuals: So-called beta-amyloid proteins, which form clumps (plaques) between neurons, and tau proteins, which stick together the inside of neurons. The causes of these deposits are as yet unclear. In addition, a rapidly progressive atrophy, i.e. a shrinking of the brain volume, can be observed in affected persons. Alzheimer s symptoms such as memory loss, disorientation, agitation and challenging behavior are the consequences.
Scientists at the DZNE led by Prof. Michael Wagner, head of a research group at the DZNE and senior psychologist at the memory clinic of the University Hospital Bonn, have now found in a study that a regular Mediterranean-like dietary pattern with relatively more intake of vegetables, legumes, fruit, cereals, fish and monounsaturated fatty acids, such as from olive oil, may protect against protein
PET Imaging Adds Valuable Information to Brain Metastasis Monitoring
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.
May 5, 2021 For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable information about the effectiveness of state-of-the-art treatments. When treatment monitoring with contrast-enhanced magnetic resonance imaging (MRI) is unclear, adding 18F-FET PET can help to accurately diagnose recurring brain meta
E-Mail
IMAGE: After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row). view more
Credit: Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.
Reston, VA For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable information about the effectiveness of state-of-the-art treatments. When treatment monitoring with contrast-enhanced magnetic resonance imaging (MRI) is unclear, adding 18F-FET PET can help to accurately diagnose recurring brain metastases and reliably assess patient response. This research was published in The
Journal of Nuclear Medicine.
E-Mail
WASHINGTON - The Society for Cardiovascular Angiography and Interventions (SCAI) presented its Master Interventionalists of SCAI (MSCAI) designations during the SCAI 2020 Scientific Sessions Virtual Conference MSCAI recognition ceremony.
The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication, and teaching.
This year s MSCAI designations were awarded to the following group of outstanding interventionalists:
Ian C. Gilchrist, MD, MSCAI
Dr. Ian C. Gilchrist is a professor of medicine for Penn State University s College of Medicine at the Hershey Medical Center in Hershey, PA. Dr. Gilchrist graduated from Dartmouth College in Hanover, NH and then obtained his medical degree from Columbia University. He received his residency and cardiology fellowship training at the St. Luke s/Roosevelt Hosp
E-Mail
WASHINGTON - The Society for Cardiovascular Angiography and Interventions (SCAI) presented its Master Interventionalists of SCAI (MSCAI) designations during the SCAI 2020 Scientific Sessions Virtual Conference MSCAI recognition ceremony.
The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication, and teaching.
This year s MSCAI designations were awarded to the following group of outstanding interventionalists:
Ian C. Gilchrist, MD, MSCAI
Dr. Ian C. Gilchrist is a professor of medicine for Penn State University s College of Medicine at the Hershey Medical Center in Hershey, PA. Dr. Gilchrist graduated from Dartmouth College in Hanover, NH and then obtained his medical degree from Columbia University. He received his residency and cardiology fellowship training at the St. Luke s/Roosevelt Hospi